Aligos Therapeutics, Inc.
NASDAQ:ALGS
Overview | Financials
Company Name | Aligos Therapeutics, Inc. |
Symbol | ALGS |
Currency | USD |
Price | 9.48 |
Market Cap | 58,441,802 |
Dividend Yield | 0% |
52-week-range | 6.76 - 30 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Website | https://www.aligos.com |
An error occurred while fetching data.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD